SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.

Shanghai Shyndec Pharmaceutical Co., Ltd.

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
12.23 ^CNY	+2.34%		+12.51%	+24.92%

Jul. 12	Shyndec Pharma Unit Gets Rights for Ceftazidime Avibactam Sodium for Injection	MT
Jul. 09	Shanghai Shyndec Pharmaceutical Obtains Drug Registration for Anti-Tumor Injection; Shares Jump 9%	MT

Sinopharm Weiqida Pharmaceutical Co.,Ltd. announced that it has received CNY 372 million in funding from Shanghai Shyndec Pharmaceutical Co., Ltd.

January 22, 2021

On January 23, 2021, Sinopharm Weiqida Pharmaceutical Co.,Ltd. closed the transaction.

Latest news about Shanghai Shyndec Pharmaceutical Co., Ltd.

Shyndec Pharma Unit Gets Rights for Ceftazidime Avibactam Sodium for Injection	Jul. 12	MT
Shanghai Shyndec Pharmaceutical Obtains Drug Registration for Anti-Tumor Injection; Shares Jump 9%	Jul. 09	MT
Shyndec Pharma Unit Gets China Nod for Analgesic Ingredient	Jun. 14	MT
Shyndec Pharma Unit Gets China Nod for Conjunctivitis Eye Drops	Jun. 14	MT
China Grants Registration Approval for Shanghai Shyndec Pharmaceutical Unit's Flu Injection	May. 15	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets	Apr. 16	MT
China stocks rise after new guidelines; HK shares drop	Apr. 15	RE
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials	Apr. 10	MT
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator	Mar. 27	MT
Shyndec Pharma's Unit Gets Regulatory Nod for Sheep Vaccine	Mar. 07	MT
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation	Feb. 20	MT
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation	Feb. 20	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Jan. 25	CI
Shyndec Pharma Unit Obtains Antihistamine Marketing Rights for 7.7 Million Yuan	Jan. 03	MT
China Grants Supplementary Drug Approval for Shyndec Pharmaceutical Subsidiaries' Antibiotic, Hypertension Tablets	Dec. 08	MT
Shyndec Pharma Passes Drug GMP Compliance Inspection	Nov. 28	MT
Shyndec Pharmaceutical's Drug Chosen for China's Centralized Bid	Nov. 08	MT
Shyndec Pharmaceutical Unit's Cefprozil Tablets Passes Regulatory Evaluation	Nov. 07	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Shyndec Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride's Listing	23-09-19	MT
Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) added to S&P Global BMI Index	23-09-18	CI
Shanghai Shyndec Pharma Gets Nod to Market Blood Sugar Drug Ingredient	23-09-14	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-24	CI
Shyndec Pharmaceutical's Unit Gets Nod for Registration of Oprinone Hydrochloride Injection	23-07-06	MT

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

Duration

Period

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

More charts

SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

Sector

Pharmaceuticals

Calendar

2024-08-28 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

12.23

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+24.92%	2.26B
MERCK KGAA	+7.04%	73.13B
KYOWA KIRIN CO. LTD.	+31.10%	10.38B
YUHAN CORPORATION	+37.94%	5.16B
SK BIOPHARMACEUTICALS CO., LTD.	-17.33%	4.73B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+21.49%	3.81B
BETTA PHARMACEUTICALS CO., LTD.	-36.84%	1.88B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-43.31%	1.77B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B
SUPERNUS PHARMACEUTICALS, INC.	-1.11%	1.57B

Specialty & Advanced Pharmaceuticals

Shanghai Shyndec Pharmaceutical Co., Ltd.

Equities

600420

CNE000001JG2

Pharmaceuticals

Sinopharm Weiqida Pharmaceutical Co.,Ltd. announced that it has received CNY 372 million in funding from Shanghai Shyndec Pharmaceutical Co., Ltd.

Latest news about Shanghai Shyndec Pharmaceutical Co., Ltd.

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals